Pacira BioSciences Reports $35 Mln Increase In Q2 Prel. Revenue

Non-opioid pain management solution company, Pacira BioSciences, Inc. (PCRX), has announced its preliminary results for the second quarter on Thursday. The company reported a better quarter year-over-year with an increase in revenue propelled by the sale of EXPAREL and ZILRETA, two of the company's major productions.

The preliminary revenue reported by the company was $169.4 million this year, compared to $135.6 million last year. EXPAREL sales increased to $137.0 million from $130.1 million last year while the sales of ZILRETA increased to $27.4 million in the quarter.

The company also said that despite the regression of the pandemic, some of the elective surgery procedures are still under restriction, impacting the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT